Orphan Drugs Market
Orphan Drugs Market Global Industry Assessment & Forecast
#
Pages:
169
2021
Nov - 2021
VMR-2021-0236
Segments Covered
By
Disease Type Oncologic Diseases, Metabolic Diseases, Hematologic & Immunologic Diseases, Infectious Diseases, Neurologic Diseases, Other Rare Diseases
-
By
Indication Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Cystic Fibrosis, Glioma, Pancreatic Cancer, Ovarian Cancer, Multiple Myeloma, Duchenne Muscular Dystrophy, Graft vs Host Disease, Renal Cell Carcinoma, Others
Snapshot
 Forecast
Years:
|
2021 - 2028 |
 Historical
Years:
|
2016 - 2020 |
 Revenue
2021: |
112.36 Billion |
 Revenue 2028:
|
3199.3 Billion |
 Revenue CAGR
(2021 - 2028): |
7.4 |
Fastest Growing Region (2022 -
2028)
|
North America |
Customization Offered
Cross-segment Market Size and
Analysis
for Mentioned Segments- Additional Company Profiles (Upto 5
With
No Cost)
- Additional Countries (Apart From
Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request
Customization Speak To
Analyst
FAQ
Frequently Asked Question
What is the global demand for Orphan Drugs in terms of revenue?
-
The global Orphan Drugs valued at 112.36 Billion in 2020 and is expected to reach 3199.3 Billion in 2028 growing at a CAGR of 7.4%.
Which are the prominent players in the market?
-
The prominent players in the market are RegeneRX Biopharmaceuticals Inc., F.Hoffman-La Roche AG, Pfizer Inc., Shire PLC, AbbVie Inc., Alexion, Bayer, Celgene Corporation, Johnson & Johnson Services Inc., Sanofi, Novartis AG, Merck & Co. Inc., Amryt Pharma PLC, Brisol-Myers Squibb Company..
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 7.4% between 2021 and 2028.
What are the driving factors fueling the growth of the market?
-
The driving factors of the Orphan Drugs include
- Demand has increased substantial for the orphan drugs due to surge in occurrence of rare diseases. Furthermore, the increase in awareness with respect to rare diseases among the populace, rise in investment in R&D, and drug development is fueling the market growth.
- Rising healthcare spending nd improving healthcare infrastrcture is another driving factor for the market.
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Orphan Drugs in 2020.
